| 86R3248 EAS-F  
---|---  
|  By: Paddie | H.B. No. 2050  
---  
|  A BILL TO BE ENTITLED  
|  AN ACT  
| relating to consent requirements for the prescription of certain  
| psychoactive medications to residents of nursing facilities and  
| related institutions.  
|  BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:  
|  SECTION 1. Section 242.505, Health and Safety Code, is  
| amended by amending Subsection (c) and adding Subsections (g), (h),  
| and (i) to read as follows:  
|  (c) _Subject to Subsection (g), consent_ [ ~~Consent~~ ] to the  
| prescription of psychoactive medication given by a resident or by a  
| person authorized by law to consent on behalf of the resident is  
| valid only if:  
|  (1) the consent is given voluntarily and without  
| coercive or undue influence;  
|  (2) the person prescribing the medication or that  
| person's designee provided the following information, in a standard  
| format approved by the department, to the resident and, if  
| applicable, to the person authorized by law to consent on behalf of  
| the resident:  
|  (A) the specific condition to be treated;  
|  (B) the beneficial effects on that condition  
| expected from the medication;  
|  (C) the probable clinically significant side  
| effects and risks associated with the medication; and  
|  (D) the proposed course of the medication;  
|  (3) the resident and, if appropriate, the person  
| authorized by law to consent on behalf of the resident are informed  
| in writing that consent may be revoked; and  
|  (4) the consent is evidenced in the resident's  
| clinical record by _:_  
|  _(A)_ a signed form prescribed by the facility or  
| by a statement of the person prescribing the medication or that  
| person's designee that documents that consent was given by the  
| appropriate person and the circumstances under which the consent  
| was obtained _; and_  
|  _(B)_ _____the original or a copy of the written consent_  
| _required by Subsection (g), if applicable_.  
|  _(g)_ _____In addition to the requirements of Subsection (c),_  
| _consent to the prescription of an antipsychotic or neuroleptic_  
| _medication is valid only if:_  
|  _(1)_ _____the consent to the prescription of that medication_  
| _is given in writing by a resident or by a person authorized by law to_  
| _consent on behalf of the resident; and_  
|  _(2)_ _____the person prescribing the medication or that_  
| _person's designee provides the information listed in Subsection_  
| _(h), in a standard format approved by the department, to the_  
| _resident and, if applicable, to the person authorized by law to_  
| _consent on behalf of the resident._  
|  _(h)_ _____The information required under Subsection (g)(2) must_  
| _include:_  
|  _(1) the nature of the medication;_  
|  _(2)_ _____the means of administering the medication,_  
| _including:_  
|  _(A) the dosage;_  
|  _(B) the administration schedule;_  
|  _(C) the method of delivery; and_  
|  _(D) the expected duration of administration;_  
|  _(3)_ _____the right of the resident or a person authorized by_  
| _law to consent on behalf of the resident to refuse medication;_  
|  _(4)_ _____the potential medical and clinical consequences of_  
| _refusing the medication; and_  
|  _(5)_ _____an explanation of treatment alternatives and the_  
| _right of the resident or a person authorized by law to consent on_  
| _behalf of the resident to choose such treatments._  
|  _(i)_ _____In addition to other requirements of this section,_  
| _before administering an antipsychotic or neuroleptic medication,_  
| _the facility shall inform the resident or a person authorized to_  
| _consent on behalf of the resident about facility policies and_  
| _procedures relating to consent and, on request of the resident or_  
| _authorized person, shall make available a written copy of those_  
| _policies and procedures._  
|  SECTION 2. This Act takes effect September 1, 2019.

